Clinical Trial Update: A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a respiratory vaccine given with Tdap in healthy nonpregnant adults aged 18-49; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Tract Infection

Drugs mentioned

• Pfizer RSV vaccine (investigational in this study)

Snippet

Sponsor: Pfizer | Conditions: Respiratory Tract Infection | Phase 2 | Status: COMPLETED | Results posted: 2021-02-15